U.S. FDA panel meets to discuss Sarepta muscular dystrophy drug

April 25 (Reuters) - Hundreds of patients and advocates

packed a hotel ballroom in Hyattsville, Maryland on Monday to

try to persuade advisors to the U.S. Food and Drug

Administration to support approval of an experimental drug to

treat Duchenne muscular dystrophy.

Read more